S100A5 and colorectal carcinoma: Niclosamide, an inhibitor of S100A4, which inhibit colorectal cancer (CRC) progression, has entered phase II clinical trials for the treatment of metastatic CRC.[66, 67] Based on our findings, anti‐S100A5 therapy might have the ability to turn “cold” tumors into “hot” tumors and show higher effectiveness in combination with ICIs.